Breast Cancer Recurrence Risk Calculator

Breast cancer recurrence risk is the probability that cancer will return after initial treatment — either in the same breast (local), in the lymph nodes (regional), or elsewhere in the body (distant/metastatic). This calculator estimates risk based on established clinical factors including tumor size, grade, lymph node status, hormone receptor type, and treatments received. It uses a weighted scoring model derived from published breast oncology research.

Hormone receptor status (ER/PR positive or negative) is one of the strongest predictors of recurrence type and timing. Hormone receptor-positive (ER+/PR+) cancers tend to have a lower short-term recurrence risk but can recur years or even decades later. Triple-negative and HER2+ cancers carry a higher early recurrence risk but typically do not continue rising as steeply over 10+ years. Hormonal therapy such as tamoxifen or aromatase inhibitors significantly reduces recurrence risk in ER+ cases.

Most clinical guidelines recommend 5 to 10 years of hormonal therapy (tamoxifen or an aromatase inhibitor) for hormone receptor-positive breast cancer. Extended therapy beyond 5 years has been shown to further reduce the risk of late recurrence, particularly in women with higher-risk tumor features. Your oncologist will weigh the benefits against side effects and individual health factors to determine the optimal duration for you.

The Tyrer-Cuzick model is a validated statistical tool that estimates a woman's lifetime risk of developing breast cancer based on personal, hormonal, and family history factors, including BRCA mutation status. It is widely used by breast cancer clinics to determine eligibility for enhanced screening, preventive medications, or prophylactic surgery. This recurrence risk calculator draws on similar risk factor principles to estimate post-treatment recurrence probability.

Generally, a 5-year recurrence risk above 15% is considered elevated, and above 30% is considered high risk in clinical practice. However, risk thresholds vary by cancer type and clinical context. Low-risk scores (below 10%) are often associated with small, low-grade, hormone receptor-positive tumors with no lymph node involvement treated with hormonal therapy. Always discuss your specific risk score with your oncologist to interpret it in the context of your full medical history.

A BRCA1 or BRCA2 mutation increases the risk of a new primary breast cancer in the same or opposite breast, which is distinct from true recurrence but equally important. BRCA-positive individuals also face elevated risks of ovarian cancer. If you carry a BRCA mutation, your care team may recommend more aggressive surveillance, extended preventive therapy, or consideration of risk-reducing surgery such as prophylactic mastectomy.

If your family history is unknown, select 'No' for first-degree relative history and 'Not Tested / Unknown' for BRCA status. The calculator will estimate your risk based on your personal clinical factors alone. While this may slightly underestimate risk if there is an unknown hereditary component, your tumor characteristics and treatment details remain the dominant drivers of recurrence risk in this model.

No — this tool is for educational and informational purposes only. It provides a general risk estimate based on population-level data and simplified inputs, and cannot account for all individual variables such as specific genetic panel results, pathology details, or comorbidities. Always consult a qualified oncologist or breast cancer specialist for personalized risk assessment and treatment planning.